Patents by Inventor Franz Paul Armbruster

Franz Paul Armbruster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220008620
    Abstract: A prosthetic polylactide or collagen-containing scaffold material for treating osseous defects and neogenesis of bone, obtained by printing a scaffold composed of strings of polylactide and porous microstructures which allow passage and ingrowth of bone tissue. A soluble mixture of BSP and/or collagen is provided, and BSP and/or collagen is applied onto the strings and in the pores of the printed body to obtain a prosthetic material which induces tissue-directed ingrowth of bone tissue as well as repair and healing of damaged or diseased bone tissues and lesions. The prosthetic material is osseo-inductive and osseo-conductive. The BSP in the prosthetic scaffold material induces a tissue-directed growth of osseous tissue. No undirectional callous or overgrowing bone and cartilage tissue is observed.
    Type: Application
    Filed: November 8, 2019
    Publication date: January 13, 2022
    Applicants: Immundiagnostik AG, Johannes Gutenberg-Universitat Mainz
    Inventors: Franz Paul ARMBRUSTER, Pol Maria ROMMENS, Ulrike RITZ
  • Patent number: 11221337
    Abstract: A method comprising the steps of: (a) collecting a stool sample with the analyte and transferring a defined amount of stool sample into a prepared vessel having a sieve filter and a predetermined amount of extraction solution; (b) suspending and extracting the stool sample in the extraction solution so that the analyte goes into solution; (c) filtering the extraction solution through the sieve filter and transferring a defined amount of extraction solution to a cellulosic fibrous web having predetermined absorbency; (d) rapid drying of the extraction solution on the cellulose fibrous web at ambient temperature by the capillary action of the fibrous web, wherein the fibrous web with the sample extraction solution represents a storage and transport form stable over days and weeks, on which analyte and digestive enzymes are physically separated from each other; (e) collecting and extracting the analyte from the fibrous web in a predetermined amount of assay buffer; (f) separating the fibrous web from the assay b
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: January 11, 2022
    Assignees: IMMUNDIAGNOSTIK AG
    Inventors: Hans-Juergen Groen, Franz-Paul Armbruster
  • Publication number: 20210404920
    Abstract: A method for pre-analytical treatment of a serum or plasma sample from a patient suspected of suffering from oxidative stress, which includes contacting the sample with one or more microcapsules having a gelled alginate core and a semipermeable coating, where the alginate core includes dispersed receptors against an oxidised human parathyroid hormone (PTH) peptide. The semipermeable membrane can be obtained by layer-by-layer deposition of polycationic and polyanionic macromolecules onto the gelled core, following by hardening, crosslinking and co-acervation of the macroionic phases.
    Type: Application
    Filed: August 20, 2019
    Publication date: December 30, 2021
    Applicant: IMMUNDIAGNOSTIK AG
    Inventors: Franz-Paul ARMBRUSTER, Anja HELMSCHRODT
  • Publication number: 20210382044
    Abstract: A method for measuring the presence of calprotectin (S100A8/A) heterodimer in a biological sample using a particle-enhanced turbidimetric immunoassay (PETIA) based on monoclonal antibodies. The method can be adapted on automated standard analyzers and provides a reliable clinical measurement of calprotectin in faecal samples and extracts. The method is comparable to commerical two-site sandwich ELISA. The disclosed method counters spontaneous agglutination caused by calcium ions and low-molecular weight calcium-binding S100 proteins as observed with conventional PETIAs. The method can be used for measuring the presence of human calprotectin in stool, urine, serum, plasma, synovial liquid and other body liquids. Metrological traceability and high commutability with conventional immunoassays (ELISA) has been shown despite of different measurement principles used.
    Type: Application
    Filed: May 9, 2018
    Publication date: December 9, 2021
    Applicants: Immundiagnostik AG, Diasys Diagnostic Systems GmbH
    Inventors: Franz-Paul Armbruster, Matthias Grimmler, Pia Schu, Tobias Becker, Felix Walzer
  • Patent number: 11085922
    Abstract: A method for detecting and quantifying anti-neutrophil-cytoplasmic antibodies (ANCA) in a sample of bodily fluid from a patient suspected of suffering from an autoimmune disease, including the steps of contacting human polymorphonuclear neutrophils able to release extracellular traps (NETs) with microspheres to produce NET-coated microspheres, contacting the NET-coated microspheres with the sample of bodily fluid, and labeling and subsequent analyzing of anti-neutrophil-cytoplasmic antibodies by flow cytometric methods.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 10, 2021
    Assignee: Immundiagnostik AG
    Inventors: Franz Paul Armbruster, Moritz Leppkes
  • Publication number: 20210172945
    Abstract: An analyte testing system for quantifying the presence of an analyte in a speciment by lateral flow chromatography. The system comprises a test cassette (10) with a lateral flow chromatography and a mobile hand-held processor device (16) comprising a digital camera (16a), a source of light (16b) and a processor (16c), which software and hardware (16c) are configured to determine automatically the distance between camera and object and the measures of light in the region of interest of the lateral flow chromatography prior any retrieval of image data for further analysis and quantification of the visual signals.
    Type: Application
    Filed: May 7, 2019
    Publication date: June 10, 2021
    Applicant: Immundiagnostik AG
    Inventors: Franz Paul Armbruster, Felix Walzer, Ben John
  • Patent number: 10947301
    Abstract: A novel therapy concept based on a removal of circulating BSP (bone sialoprotein) from the plasma of patients with chronic kidney disease (CKD) or highly at risk of developing arterial and vascular calcifications. The method comprises method of treatment of extracellular tissue and vascular calcifications, atherosclerosis, arteriosclerosis, and arterial calcification. The beneficial effects of this therapy have been proven by the observed correspondence between levels of circulating free BSP levels and mortality of CKD patients as well as in animal models.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: March 16, 2021
    Assignee: Immundiagnostik AG
    Inventors: Franz Paul Armbruster, Berthold Hocher
  • Publication number: 20210072263
    Abstract: Test kit, composition and a method of measuring vitamin D and its metabolites in a sample of bodily fluid from a subject, which sample contains vitamin D binding protein (DBP), comprising the steps of contacting said sample with megalin and/or a soluble fragment thereof under binding conditions to form a ternary complex containing DBP, a vitamin D metabolite and megalin or a fragment thereof; determining the amount of DBP bound by megalin; and relating the amount of megalin-bound DBP to the effective status of vitamin D in the circulation of said subject.
    Type: Application
    Filed: January 3, 2019
    Publication date: March 11, 2021
    Applicant: Immundiagnostik AG
    Inventors: Franz Paul Armbruster, Liliana Schaefer
  • Publication number: 20200371118
    Abstract: Method of determining the health risk for myocardial infartion inpatients subjected to coronary angiography or suspected having an increased cardio-vascular health risk, wherein the concentration of parathyroid hormone is determined in vitro in serum or plasma sample of said patient wherein that the serum or plasma sample is contacted with beads binding oxidized parathyroid hormone and correlating the determined level of parathyroid hormone to the risk for myocardial infarction.
    Type: Application
    Filed: January 17, 2019
    Publication date: November 26, 2020
    Applicant: Immundiagnostik AG
    Inventors: Franz Paul ARMBRUSTER, Thomas B. DSCHIETZIG
  • Publication number: 20200209252
    Abstract: A method comprising the steps of: (a) collecting a stool sample with the analyte and transferring a defined amount of stool sample into a prepared vessel having a sieve filter and a predetermined amount of extraction solution; (b) suspending and extracting the stool sample in the extraction solution so that the analyte goes into solution; (c) filtering the extraction solution through the sieve filter and transferring a defined amount of extraction solution to a cellulosic fibrous web having predetermined absorbency; (d) rapid drying of the extraction solution on the cellulose fibrous web at ambient temperature by the capillary action of the fibrous web, wherein the fibrous web with the sample extraction solution represents a storage and transport form stable over days and weeks, on which analyte and digestive enzymes are physically separated from each other; (e) collecting and extracting the analyte from the fibrous web in a predetermined amount of assay buffer; (f) separating the fibrous web from the assay b
    Type: Application
    Filed: May 11, 2018
    Publication date: July 2, 2020
    Applicants: IMMUNDIAGNOSTIK AG
    Inventors: Hans-Juergen GROEN, Franz-Paul ARMBRUSTER
  • Patent number: 10613101
    Abstract: A new method of in vitro monitoring and assessing the need of a medication which interferes with the regulation of the parathyroid hormone level in a kidney patient subject to oxidative stress, notably hemodialysis patients. FIG. 1 shows the distribution of n-oxPTH concentrations in 340 hemodialysis patients (224 men and 116 women) with a median age of 66 years (IQR, 56 to 75 years), a median time since initiation of dialysis (dialysis vintage) of 266 days (IQR, 31 to 1209 days), and a median dialysis dose (kt/V) of 1.2 (IQR, 1.1 to 1.3). The cause of chronic kidney disease was nephrosclerosis in 113 cases (33%), diabetic nephropathy in 107 cases (31%), chronic glomerular nephritis in 29 cases (9%), polycystic kidney disease in 9 cases (3%) and other/unknown in 82 cases (24%). The median n-oxPTH concentration was 5.9 ng/L (IQR, 2.4 to 14.0 ng/L). n-oxPTH concentrations were not different in men and women (5.9 ng/L; IQR, 2.4 to 14.2 ng/L; n=224; vs. 5.5 ng/L; IQR, 2.4 to 14.0 ng/L; n=116; p=0.915).
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: April 7, 2020
    Assignee: Immundiagnostik AG
    Inventors: Franz Paul Armbruster, Berthold Hocher, Heinz Jürgen Roth
  • Publication number: 20190204311
    Abstract: The disclosure relates to a method for detecting and quantifying anti-neutrophil-cytoplasmic antibodies (ANCA) in a sample of bodily fluid from a patient suspected of suffering from an autoimmune disease, comprising the steps of contacting human polymorphonuclear neutrophils able to release extracellular traps (NETs) with microspheres, so that NET-coated microspheres are produced: contacting said NET-coated microspheres with said sample of bodily fluid suspected of containing anti-neutrophil-cytoplasmic antibodies; and labeling and subsequent analyzing of anti-neutrophil-cytoplasmic antibodies by flow cytometric methods.
    Type: Application
    Filed: December 13, 2018
    Publication date: July 4, 2019
    Inventors: Franz Paul ARMBRUSTER, Moritz LEPPKES
  • Publication number: 20190177403
    Abstract: A novel therapy concept based on a removal of circulating BSP (bone sialoprotein) from the plasma of patients with chronic kidney disease (CKD) or highly at risk of developing arterial and vascular calcifications. The method comprises method of treatment of extracellular tissue and vascular calcifications, atherosclerosis, arteriosclerosis, and arterial calcification. The beneficial effects of this therapy have been proven by the observed correspondence between levels of circulating free BSP levels and mortality of CKD patients as well as in animal models.
    Type: Application
    Filed: February 22, 2019
    Publication date: June 13, 2019
    Inventors: Franz Paul Armbruster, Berthold Hocher
  • Patent number: 10317419
    Abstract: A method is disclosed for obtaining an antibody or antibody fragment to a conformational epitope specific for misfolded inactive human parathyroid hormone and fragments thereof. The method includes the steps of a) immunizing an animal with an immunogen which comprises oxidized parathyroid hormone or an oxidized fragment of parathyroid hormone, or both; and b) recovering an antibody, antibody fragments, or single chain antibody. The complementary determining region of the recovered antibody, antibody fragment or single chain antibody is capable of specifically recognizing a conformational epitope (antigenic determinant) which is present on oxidized parathyroid hormone and fragments thereof only but not regular bioactive human parathyroid hormone.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: June 11, 2019
    Assignee: Immundiagnostik AG
    Inventors: Franz Paul Armbruster, Berthold Hocher, Hans Juergen Groen, Heinz Juergen Roth
  • Patent number: 10253092
    Abstract: The present invention provides a novel therapy concept based on a removal of circulation BSP (bone sialoprotein) from the plasma of patients with chronic kidney disease (CKD), preferably by plasmapheresis or an administration of antibodies against BSP in plasma. The present invention further provides a BSP absorber material for plasmapheresis and a pharmaceutical composition namely in form of anti-BSP antibodies for direct administration which are biocompatible in humans. The beneficial effects of this therapy have been proven by the observed correspondence between levels of circulating free BSP levels and mortality of CKD patients.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: April 9, 2019
    Assignee: Immundiagnostik AG
    Inventors: Franz Paul Armbruster, Berthold Hocher
  • Patent number: 9823258
    Abstract: Method of diagnosis and prognosis of contrast media induced nephropathy (CIN) including the steps of i) taking a urine sample from a patient exposed to the application of contrast media, notably patients subjected to coronary angiography; ii) assessing the level of vitamin D binding protein (VDBP) in the urine sample obtained in step (i); iii) relating the urinary vitamin D binding protein level determined in step (ii) to a pre-selected threshold level. A urinary vitamin D binding protein level higher than the pre-selected threshold level indicates that the patient is at risk of renal failure and in need of a dialysis treatment.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: November 21, 2017
    Assignee: Immundiagnostik AG
    Inventors: Franz Paul Armbruster, Berthold Hocher
  • Publication number: 20170204172
    Abstract: The present invention provides a novel therapy concept based on a removal of circulation BSP (bone sialoprotein) from the plasma of patients with chronic kidney disease (CKD), preferably by plasmapheresis or an administration of antibodies against BSP in plasma. The present invention further provides a BSP absorber material for plasmapheresis and a pharmaceutical composition namely in form of anti-BSP antibodies for direct administration which are biocompatible in humans. The beneficial effects of this therapy have been proven by the observed correspondence between levels of circulating free BSP levels and mortality of CKD patients.
    Type: Application
    Filed: February 17, 2017
    Publication date: July 20, 2017
    Applicant: lmmundiagnostik AG
    Inventors: Franz Paul Armbruster, Berthold Hocher
  • Publication number: 20170059584
    Abstract: Method of diagnosis and prognosis of contrast media induced nephropathy (CIN) comprising the steps of i) taking a urine sample from a patient exposed to the application of contrast media, notably patients subjected to coronary angiography; ii) assessing the level of vitamin D binding protein (VDBP) in the urine sample obtained in step (i); iii) relating the urinary vitamin D binding protein level determined in step (ii) to a pre-selected threshold level, wherein a urinary vitamin D binding level higher than said pre-selected threshold level indicates that the patient is at risk of renal failure and in need of a dialysis treatment.
    Type: Application
    Filed: February 20, 2015
    Publication date: March 2, 2017
    Applicant: Immundiagnostik AG
    Inventors: Franz Paul ARMBRUSTER, Berthold HOCHER
  • Publication number: 20160025748
    Abstract: A new method of in vitro monitoring and assessing the need of a medication which interferes with the regulation of the parathyroid hormone level in a kidney patient subject to oxidative stress, notably hemodialysis patients. FIG. 1 shows the distribution of n-oxPTH concentrations in 340 hemodialysis patients (224 men and 116 women) with a median age of 66 years (IQR, 56 to 75 years), a median time since initiation of dialysis (dialysis vintage) of 266 days (IQR, 31 to 1209 days), and a median dialysis dose (kt/V) of 1.2 (IQR, 1.1 to 1.3). The cause of chronic kidney disease was nephrosclerosis in 113 cases (33%), diabetic nephropathy in 107 cases (31%), chronic glomerular nephritis in 29 cases (9%), polycystic kidney disease in 9 cases (3%) and other/unknown in 82 cases (24%). The median n-oxPTH concentration was 5.9 ng/L (IQR, 2.4 to 14.0 ng/L). n-oxPTH concentrations were not different in men and women (5.9 ng/L; IQR, 2.4 to 14.2 ng/L; n=224; vs. 5.5 ng/L; IQR, 2.4 to 14.0 ng/L; n=1 16; p=0.915).
    Type: Application
    Filed: March 7, 2014
    Publication date: January 28, 2016
    Applicant: Immundiagnostik AG
    Inventors: Franz Paul Armbruster, Berthold Hocher, Heinz Jürgen Roth
  • Publication number: 20150017738
    Abstract: Method for obtaining an antibody or antibody fragment to a conformational epitope specific for oxidized, inactive human parathyroid hormone and fragments thereof; a method for removal of oxidized, inactive human parathyroid hormone from a sample of body fluid; methods of determining the concentration of active parathyroid hormone in a sample, and an in vitro method of diagnosis of renal failure or secondary hyperthyroidism in patients on dialysis.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 15, 2015
    Applicant: Immundiagnostik AG
    Inventors: Franz Paul Armbruster, Berthold Hocher, Hans Juergen Groen, Heinz Juergen Roth